Hot Investor Mandate: Large China Biologics Company Seeks Novel Antibody Product Candidates for Potential In-Licensing and Strategic Partnership

18 Jul

A large biologics company headquartered in China with additional operations in USA and Asia, focuses on the development and commercialization of antibody-based therapeutics using advanced technologies. The company has a special focus on biosimilars and biobetters (mAbs and recombinant proteins) for malignant tumors (including solid tumor, lymphoma, etc.) and auto-immune diseases. Currently, the company’s pipeline covers over 8 biosimilars and 10 novel antibody products in pre-clinical and clinical development.

In addition to seeking out-licensing opportunities and strategic partnerships, the company is also seeking to in-license novel antibody product candidates in oncology that has synergies with the company’s current portfolio.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: